Indication

Anemia in myelodysplastic syndrome with ring sideroblasts

Anemia in myelodysplastic syndrome with ring sideroblasts is a hematologic manifestation of a clonal hematopoietic stem cell neoplasm primarily affecting older adults. Read more about Anemia in myelodysplastic syndrome with ring sideroblasts

2 drugs 2 manufacturers

Advertisement

Drugs that treat it

Common Anemia in myelodysplastic syndrome with ring sideroblasts therapies.

Showing 1–2 of 2 drugs

Filter & compare in the drug finder →Opens the drug finder with Anemia in myelodysplastic syndrome with ring sideroblasts preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Anemia in myelodysplastic syndrome with ring sideroblasts.

Anemia in myelodysplastic syndrome with ring sideroblasts is a hematologic manifestation of a clonal hematopoietic stem cell neoplasm primarily affecting older adults.

It is characterized by ineffective erythropoiesis that results in chronic peripheral cytopenia and potential transfusion dependence.

Pathophysiologically, the condition is defined by the accumulation of iron within the mitochondria of erythroid precursors, visible on bone marrow evaluation as a collar of perinuclear iron granules encircling at least one-third of the nucleus.

This subtype is frequently driven by somatic mutations in the RNA splicing machinery gene *SF3B1*, which lead to abnormal mitochondrial iron handling, maturation arrest in late-stage erythroblasts, and a heightened risk of secondary systemic iron overload.

Personalize your experience

Follow Anemia in myelodysplastic syndrome with ring sideroblasts and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it